TLSI
TriSalus Life Sciences, Inc. (TLSI) Business Model Analysis (2026)
Overall Score
Revenue Model
The company generates revenue, but TTM price-to-sales of 6.60 suggests the market is still assigning a meaningful growth premium.
Revenue per share is 0.77, indicating a relatively small current revenue base.
Profitability
Gross margin is very strong at 85.8%, showing the core product/service economics are attractive.
However, EBITDA margin (-48.1%), operating margin (-67.7%), and net margin (-62.6%) are deeply negative on a TTM basis.
Capital Efficiency
Asset turnover of 0.72 and fixed-asset turnover of 17.1 indicate the asset base is being used to generate sales.
Current ratio of 5.35 and cash ratio of 4.14 show strong short-term liquidity.
Balance Sheet
Liquidity is strong, supported by a current ratio of 5.35 and cash per share of 0.79.
Debt-to-market-cap is only 0.11, suggesting leverage is not overwhelming relative to equity value.
Growth Durability
The business still has a viable operating footprint, with gross profit margin remaining high despite losses.
The market is valuing the company at a premium sales multiple, implying some expectation of future durability.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on TriSalus Life Sciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

